Un ejemplo reciente en este campo es el hallazgo de que pacientes con c\u00e1ncer de mama y de ovario familiar portadoras de mutaciones en el gen BRCA1 son m\u00e1s sensibles a los f\u00e1rmacos denominados inhibidores de una prote\u00edna llamada PARP (poli-adenosina difosfato ribosa polimerasa). El problema radica en que s\u00f3lo cuatro de cada cien pacientes de c\u00e1ncer de mama se beneficiar\u00edan de este tratamiento porque la mutaci\u00f3n de BRCA1 ocurre infrecuentemente. <\/p>\n
La revista oficial de la Sociedad Americana de Oncolog\u00eda M\u00e9dica (ASCO), el Journal of Clinical Oncology, ha publicado un estudio coordinado por Manel Esteller, director del Programa de Epigen\u00e9tica y Biolog\u00eda del C\u00e1ncer del Instituto de Investigaci\u00f3n Biom\u00e9dica de Bellvitge (IDIBELL), que extiende el n\u00famero de pacientes susceptibles de recibir este tratamiento. <\/p>\n
El grupo del Dr. Esteller ha demostrado que la inactivaci\u00f3n epigen\u00e9tica del gen BRCA1 tambi\u00e9n confiere sensibilidad a los inhibidores de PARP en c\u00e9lulas de c\u00e1ncer de mama. Como un 25% de pacientes con c\u00e1ncer de mama presentan p\u00e9rdidas del gen BRCA1 mediante este mecanismo, se abre la posibilidad de que una de cada cuatro mujeres con tumores de mama se puedan beneficiar de este nuevo tratamiento personalizado.<\/p>\n
Los autores del estudio sugieren que se incluyan an\u00e1lisis para detectar la inactivaci\u00f3n epigen\u00e9tica del gen BRCA1 en los ensayos cl\u00ednicos que se llevan a cabo para probar la eficacia de los PARP en pacientes con c\u00e1ncer de mama o de ovario.<\/p>\n
Referencia del art\u00edculo:<\/strong> La inactivaci\u00f3n epigen\u00e9tica del gen BRCA1 mejora el efecto de los inhibidores de PARP en tumores de mama Referencia del art\u00edculo:<\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"no-sidebar","site-content-layout":"page-builder","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"footnotes":""},"categories":[292,281],"tags":[],"publishpress_future_action":{"enabled":false,"date":"2024-05-10 08:31:10","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"_links":{"self":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/posts\/11487"}],"collection":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/comments?post=11487"}],"version-history":[{"count":0,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/posts\/11487\/revisions"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/media?parent=11487"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/categories?post=11487"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/tags?post=11487"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
Veeck J, Ropero S, Setien F, Gonzalez-Suarez E, Osorio A, Benitez J, Herman JG, Esteller M. BRCA1 CpG Island Hypermethylation Predicts Sensitivity to Poly(Adenosine Diphosphate)-Ribose Polymerase Inhibitors. Journal of Clinical Oncology, August 2, 2010.<\/p>\n","protected":false},"excerpt":{"rendered":"